Lab-engineered meats, milks, gelatin and other
replacements for animal-based foods is a growing industry. The
purpose of these innovative products is to be as similar as
possible to their animal-based counterparts, but being identical to
naturally occurring products can pose a problem to patent
eligibility.
In the last five years, the Supreme Court has started
tightening the requirements for patent eligible inventions. In
the Myriad case in 2013, the Supreme Court
found the breast cancer genes BRCA1 and BRCA2 ineligible for patent
protection because they were "not distinguishable from"
natural genetic DNA. In 2014, the Alice case, which found
certain software-based inventions
unpatentable, laid the basis for the two-step test for patent
eligibility that the U.S. Patent and Trademark Office (USPTO) still
uses today.